YALE UNIVERSITY

West Virginia passed a bill allowing two medical research trials on opioid use disorder, comparing buprenorphine and methadone. The study, led by Yale and Pittsburgh universities, aims to improve treatment access and effectiveness, with potential implications for state laws and public perception of methadone.

Dr. Yang Liu discusses preclinical studies on the CD24/Siglec-10 pathway, highlighting the development of ONC-781 and ONC-841 antibodies, and their potential in cancer and inflammatory disease treatment.

Arc Institute adds seven leading scientists to its Investigator Program and Ignite Award cohorts, focusing on complex human diseases. Applications for 2025 Investigator and Fellow programs are open.

The A4M October Symposium, held at Encore Boston from October 24-26, 2024, features expert-led sessions on functional anti-aging medicine, including certifications in weight management, pellet therapy, IV therapy, gastroenterology, and peptide therapy. The event aims to equip practitioners with actionable skills and insights, addressing current trends and challenges in these fields.

Inebilizumab (Uplizna) demonstrated clinically meaningful efficacy and a favorable safety profile in patients with generalized myasthenia gravis (gMG), according to the MINT trial. The anti-CD19 monoclonal antibody showed a significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores at week 26 compared to placebo, with no new safety signals identified. Amgen plans to file for FDA approval based on these results.

InVita Health and Wellness uses ketamine therapy for mental health, chronic pain, and neurodegenerative disorders. Ketamine offers rapid relief for mental health conditions by rewiring the brain, and is effective for chronic pain by targeting NMDA receptors. The therapy is safe when administered by knowledgeable professionals.

The FDA approved Cobenfy (xanomeline and trospium chloride, or KarXT) on Sept. 26, the first antipsychotic drug targeting cholinergic receptors for schizophrenia in adults, not dopamine receptors. Cobenfy showed fewer extrapyramidal symptoms, metabolic adverse effects, and sedation compared to other antipsychotics. John H. Krystal, MD, from Yale University, expressed excitement about the new treatment strategy. Bristol-Myers Squibb Company received the approval, with Ken Kramer from Karuna Therapeutics highlighting the significance of a new treatment option for schizophrenia. BMS is also exploring KarXT for psychosis in other diseases like Alzheimer’s.

TVGN 489 showed no dose-limiting toxicities or significant adverse events, met endpoints for viral load reduction and anti-COVID-19 responses, and all treated patients returned to baseline health within 14 days with no COVID reinfection or Long COVID observed at 6-month follow-up.

Cybrexa Therapeutics initiates Phase 2 trial of CBX-12 in platinum-resistant or refractory ovarian cancer, following positive Phase 1 results showing 40% response rate in TOP1-naïve patients. CBX-12, a first-in-class peptide-drug conjugate, leverages alphalex™ technology for targeted delivery of exatecan, a potent TOP1 inhibitor, with broad activity across multiple solid tumor types and a favorable safety profile.

Colonoscopy rates among 45-49-year-olds tripled post-2021 guideline change, but only 11.5% of eligible individuals received screening before age 50. Income and location significantly impact access, with higher-income and urban residents more likely to get screened.